title: Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells.
abstract: Her-2/neu is a tumor-associated antigen that has been targeted with both antibodies and cytotoxic T lymphocytes (CTL). Despite the isolation of Her-2/neu-reactive CTL in vaccinated patients, their therapeutic use has been limited by the observation that they often do not robustly recognize Her-2/neu(+) tumors. We sought to determine the mechanism for this escape using Ag201P and Ag201M cells, which are murine osteosarcoma tumor lines that express a functional HLA-A2/K(b) molecule. We now demonstrate that Ag201P and Ag201M express low levels of murine Her-2/neu, and that Ag201M was modestly and inconsistently recognized by an HLA-A2-restricted, Her-2/neu-reactive human CTL clone. In order to determine whether inefficient antigen processing might account for the weak recognition, COS-A2 cells were transfected with a short Her-2/neu minigene coding for the immunodominant Her-2/neu:369 epitope that did not require antigen processing or a long Her-2/neu minigene that did require antigen processing. Her-2/neu-reactive CTL clones only recognized COS-A2 cells transfected with the short minigene, indicating that lack of proper antigen processing could be responsible for the poor recognition of target cells. To confirm these results, it was demonstrated that following treatment with interferon-gamma, both Ag201P and Ag201M robustly and consistently stimulated the CTL clones. Furthermore, CTL clone recognition was enhanced following interferon-gamma treatment using another murine tumor line that expressed low levels of Her-2/neu (B16-A2/K(b)). The enhanced recognition of Ag201P and Ag201M in the presence of interferon-gamma was not due to an upregulation of Her-2/neu protein expression. Collectively, these results suggest that inefficient antigen processing of Her-2/neu can contribute to the lack of tumor recognition by CTL. These results also suggest that even tissues that express low levels of Her-2/neu might become CTL targets under conditions in which antigen processing is enhanced.
authors.affiliation: Department of Surgery, University of Chicago, 5841 S. Maryland Avenue, IL 60637, USA.
authors.forename: Barbara L F
authors.initials: BL
authors.lastname: Kaplan
authors.forename: Håkan
authors.initials: H
authors.lastname: Norell
authors.forename: Glenda G
authors.initials: GG
authors.lastname: Callender
authors.forename: Tomas
authors.initials: T
authors.lastname: Ohlum
authors.forename: Rolf
authors.initials: R
authors.lastname: Kiessling
authors.forename: Michael I
authors.initials: MI
authors.lastname: Nishimura
mesh_terms: D000818:Animals; D017951:Antigen Presentation / Q000276:immunology*; D015153:Blotting, Western; D019556:COS Cells; D045744:Cell Line, Tumor; D002522:Chlorocebus aethiops; D005455:Fluorescent Antibody Technique; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology*; D051379:Mice; D009369:Neoplasms / Q000276:immunology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000276:immunology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014162:Transfection
chemical_list: D006680:HLA Antigens; D007371:Interferon-gamma; D018719:Erb-b2 Receptor Tyrosine Kinases